“Chronic Idiopathic Constipation Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Idiopathic Constipation Market.

The Chronic Idiopathic Constipation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Idiopathic Constipation Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Idiopathic Constipation treatment therapies with a considerable amount of success over the years.

• Chronic Idiopathic Constipation companies working in the treatment market are ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others, are developing therapies for the Chronic Idiopathic Constipation treatment

• Emerging Chronic Idiopathic Constipation therapies in the different phases of clinical trials are- LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax®), and others are expected to have a significant impact on the Chronic Idiopathic Constipation market in the coming years.

• In April 2025, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company focused on advancing transformative therapies for gastrointestinal and rare diseases, announced plans to present real-world evidence at the 2025 Digestive Disease Week® (DDW), taking place May 3–6 in San Diego, CA. The presentation will showcase data on the adoption and utilization of newly approved ICD-10 codes in patients with short bowel syndrome (SBS) dependent on parenteral nutrition.

• In December 2024, NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in both children and adults, has announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for its RED (Rectal Expulsion Device). This approval enables NeurAxis to commercially market the device for testing and evaluating patients with chronic constipation caused by pelvic floor dyssynergia, particularly those who are unlikely to see improvement with increased laxative use.

• In November 2024, Ironwood Pharmaceuticals (Nasdaq: IRWD), a member of the S&P SmallCap 600®, is a leading gastrointestinal (GI) healthcare company dedicated to improving the treatment of GI diseases and setting new standards of care for GI patients. As pioneers in the development of LINZESS® (linaclotide), we are proud to lead the U.S. branded prescription market for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

Chronic Idiopathic Constipation Overview

Chronic Idiopathic Constipation is a condition characterized by long-term, unexplained difficulty in passing stool, often accompanied by infrequent bowel movements, straining, and discomfort. The term “idiopathic” indicates that the cause is unknown, as there are no identifiable underlying medical conditions contributing to the constipation. CIC can significantly affect a person’s quality of life and may result in symptoms such as bloating, abdominal pain, and a feeling of incomplete evacuation. It is typically diagnosed when other causes of constipation, such as gastrointestinal disorders or medications, are ruled out. Treatment often involves lifestyle changes, dietary modifications, and medications.

Get a Free Sample PDF Report to know more about Chronic Idiopathic Constipation Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-idiopathic-constipation-cic-pipeline-insight

Emerging Chronic Idiopathic Constipation Drugs Under Different Phases of Clinical Development Include:

• A3309: Albireo

• AJG555: EA Pharma Co., Ltd.

• linaclotide: Astellas Pharma Inc

• KWA-0711: Kissei Pharmaceutical Co., Ltd.

• Tegaserod: Novartis

• TD-5108: Theravance Biopharma

• YKP10811: SK Life Science, Inc.

• prucalopride: Movetis

• KWA-0711: Kissei Pharmaceutical Co., Ltd

• PEG 4000 (Forlax®): Ipsen

Chronic Idiopathic Constipation Pipeline Therapeutics Assessment

• Chronic Idiopathic Constipation Assessment by Product Type

• Chronic Idiopathic Constipation By Stage and Product Type

• Chronic Idiopathic Constipation Assessment by Route of Administration

• Chronic Idiopathic Constipation By Stage and Route of Administration

• Chronic Idiopathic Constipation Assessment by Molecule Type

• Chronic Idiopathic Constipation by Stage and Molecule Type

DelveInsight’s Chronic Idiopathic Constipation Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Chronic Idiopathic Constipation product details are provided in the report. Download the Chronic Idiopathic Constipation pipeline report to learn more about the emerging Chronic Idiopathic Constipation therapies

Some of the key companies in the Chronic Idiopathic Constipation Therapeutics Market include:

Key companies developing therapies for Chronic Idiopathic Constipation are – Cosmo Pharmaceuticals NV, Sanofi, Bayer AG, Valeant Pharma, Abbott, AstraZeneca PLC, Pfizer Inc, Takeda Pharma, and others.

Chronic Idiopathic Constipation Pipeline Analysis:

The Chronic Idiopathic Constipation pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Idiopathic Constipation with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Idiopathic Constipation Treatment.

• Chronic Idiopathic Constipation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Chronic Idiopathic Constipation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Idiopathic Constipation market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Idiopathic Constipation drugs and therapies

Chronic Idiopathic Constipation Pipeline Market Drivers

• Rising Prevalence of Chronic Idiopathic Constipation, Aging Population, Advancements in Drug Development, Increasing Awareness and Diagnosis Rates, Regulatory Approvals and Pipeline Expansion, Growing Investment in Gastrointestinal Research, are some of the important factors that are fueling the Chronic Idiopathic Constipation Market.

Chronic Idiopathic Constipation Pipeline Market Barriers

• However, High Clinical Trial Failure Rates, Side Effects of Available Treatments, Limited Patient Compliance, High Development Costs, Generic Competition, Regulatory Challenges, and other factors are creating obstacles in the Chronic Idiopathic Constipation Market growth.

Scope of Chronic Idiopathic Constipation Pipeline Drug Insight

• Coverage: Global

• Key Chronic Idiopathic Constipation Companies: ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others

• Key Chronic Idiopathic Constipation Therapies: LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax®), and others

• bChronic Idiopathic Constipation current marketed and Chronic Idiopathic Constipation emerging therapies

• Chronic Idiopathic Constipation Market Dynamics: Chronic Idiopathic Constipation market drivers and Chronic Idiopathic Constipation market barriers

Request for Sample PDF Report for Chronic Idiopathic Constipation Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Idiopathic Constipation Report Introduction

2. Chronic Idiopathic Constipation Executive Summary

3. Chronic Idiopathic Constipation Overview

4. Chronic Idiopathic Constipation- Analytical Perspective In-depth Commercial Assessment

5. Chronic Idiopathic Constipation Pipeline Therapeutics

6. Chronic Idiopathic Constipation Late Stage Products (Phase II/III)

7. Chronic Idiopathic Constipation Mid Stage Products (Phase II)

8. Chronic Idiopathic Constipation Early Stage Products (Phase I)

9. Chronic Idiopathic Constipation Preclinical Stage Products

10. Chronic Idiopathic Constipation Therapeutics Assessment

11. Chronic Idiopathic Constipation Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Idiopathic Constipation Key Companies

14. Chronic Idiopathic Constipation Key Products

15. Chronic Idiopathic Constipation Unmet Needs

16 . Chronic Idiopathic Constipation Market Drivers and Barriers

17. Chronic Idiopathic Constipation Future Perspectives and Conclusion

18. Chronic Idiopathic Constipation Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/